by Eric Christianson | May 2, 2021 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
There may be a new option on the horizon for current insulin users! Insulin icodec is a new insulin option currently undergoing clinical trials. The most recent trial released for insulin icodec came out in November of 2020. The trial looked at the new insulin icodec,...
by Eric Christianson | Mar 3, 2021 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Obesity is a major risk factor for many comorbidities (hypertension, dyslipidemia, osteoarthritis, sleep apnea, heart disease, type 2 diabetes) and increases all-cause and cardiovascular mortality. With over 40% of Americans qualifying as obese (body mass index ≥30...
by Eric Christianson | Feb 28, 2021 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
A new treatment for chronic weight management is likely on the way. In a recent trial, investigators looked at semaglutide for weight loss. The final results of the STEP1 trial (Semaglutide Treatment Effect in People with obesity) were recently reported in the New...
by Eric Christianson | Feb 14, 2021 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Technology continues to impact disease state management in remarkable ways. Monitoring of patients with diabetes is no exception. Both the American Diabetes Association and American Association of Clinical Endocrinologists/American College of Endocrinology make light...
by Eric Christianson | Jan 3, 2021 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists, Polypharmacy Cases And The Prescribing Cascade
The GLP-1 Agonists have grown significantly in their popularity and there are good reasons for that increase in use. They promote weight loss which is a big problem in the majority of our type 2 diabetes patients. In addition to this benefit, they have also been shown...
by Eric Christianson | Dec 16, 2020 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists, Polypharmacy Cases And The Prescribing Cascade
SGLT2s like empagliflozin, dapagliflozin, ertugliflozin, and canagliflozin are getting more use in diabetes care as time goes on. As a geriatric pharmacist, I certainly recognize that these agents have a lot of potential benefits, but they can also have adverse...
